Ken Griffin’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.41M | Sell |
364,664
-191,982
| -34% | -$756K | ﹤0.01% | 6863 |
|
|
2025
Q4 | $2.19M | Buy |
556,646
+158,420
| +40% | +$701K | ﹤0.01% | 5738 |
|
|
2025
Q3 | $1.86M | Buy |
398,226
+203,573
| +105% | +$736K | ﹤0.01% | 6222 |
|
|
2025
Q2 | $605K | Buy |
194,653
+124,044
| +176% | +$400K | ﹤0.01% | 8179 |
|
|
2025
Q1 | $239K | Buy |
70,609
+67,051
| +1,885% | +$313K | ﹤0.01% | 10091 |
|
|
2024
Q4 | $20.2K | Sell |
3,558
-244,078
| -99% | -$1.57M | ﹤0.01% | 13177 |
|
|
2024
Q3 | $1.45M | Buy |
247,636
+132,047
| +114% | +$960K | ﹤0.01% | 6129 |
|
|
2024
Q2 | $914K | Buy |
115,589
+89,063
| +336% | +$747K | ﹤0.01% | 6773 |
|
|
2024
Q1 | $247K | Buy |
+26,526
| New | +$224K | ﹤0.01% | 9887 |
|
|
2023
Q4 | – | Sell |
-28,885
| Closed | -$210K | – | 15349 |
|
|
2023
Q3 | $224K | Sell |
28,885
-191,910
| -87% | -$1.75M | ﹤0.01% | 9687 |
|
|
2023
Q2 | $2.53M | Buy |
220,795
+117,282
| +113% | +$1.21M | ﹤0.01% | 4750 |
|
|
2023
Q1 | $798K | Sell |
103,513
-58,404
| -36% | -$464K | ﹤0.01% | 7285 |
|
|
2022
Q4 | $988K | Sell |
161,917
-60,540
| -27% | -$344K | ﹤0.01% | 6844 |
|
|
2022
Q3 | $1.32M | Buy |
222,457
+139,637
| +169% | +$894K | ﹤0.01% | 6412 |
|
|
2022
Q2 | $490K | Sell |
82,820
-57,173
| -41% | -$386K | ﹤0.01% | 8703 |
|
|
2022
Q1 | $1.07M | Buy |
139,993
+71,702
| +105% | +$320K | ﹤0.01% | 7543 |
|
|
2021
Q4 | $185K | Sell |
68,291
-914,533
| -93% | -$3.12M | ﹤0.01% | 11964 |
|
|
2021
Q3 | $2.58M | Sell |
982,824
-623,670
| -39% | -$2.03M | ﹤0.01% | 5726 |
|
|
2021
Q2 | $6.63M | Buy |
1,606,494
+1,363,816
| +562% | +$6.18M | ﹤0.01% | 3855 |
|
|
2021
Q1 | $1.14M | Sell |
242,678
-591,274
| -71% | -$4.03M | ﹤0.01% | 7773 |
|
|
2020
Q4 | $5.96M | Sell |
833,952
-4,926
| -0.6% | -$47.4K | ﹤0.01% | 3388 |
|
|
2020
Q3 | $8.95M | Buy |
838,878
+314,120
| +60% | +$3.69M | ﹤0.01% | 2418 |
|
|
2020
Q2 | $6.62M | Buy |
524,758
+408,507
| +351% | +$4.75M | ﹤0.01% | 2703 |
|
|
2020
Q1 | $1.06M | Sell |
116,251
-382,157
| -77% | -$4.39M | ﹤0.01% | 5230 |
|
|
2019
Q4 | $6.95M | Buy |
498,408
+100,161
| +25% | +$1.46M | ﹤0.01% | 2650 |
|
|
2019
Q3 | $6.85M | Buy |
398,247
+255,536
| +179% | +$5.36M | ﹤0.01% | 2694 |
|
|
2019
Q2 | $3.88M | Buy |
+142,711
| New | +$3.27M | ﹤0.01% | 3459 |
|
|
2019
Q1 | – | Sell |
-31,619
| Closed | -$412K | – | 9924 |
|
|
2018
Q4 | $297K | Sell |
31,619
-20,691
| -40% | -$266K | ﹤0.01% | 7294 |
|
|
2018
Q3 | $990K | Buy |
+52,310
| New | +$1M | ﹤0.01% | 5563 |
|
|
2018
Q2 | – | Sell |
-76,603
| Closed | -$1.44M | – | 9340 |
|
|
2018
Q1 | $1.44M | Sell |
76,603
-19,334
| -20% | -$418K | ﹤0.01% | 4238 |
|
|
2017
Q4 | $1.59M | Sell |
95,937
-154,447
| -62% | -$2.65M | ﹤0.01% | 3953 |
|
|
2017
Q3 | $5.16M | Buy |
+250,384
| New | +$2.83M | ﹤0.01% | 2280 |
|
Other funds holding VYGR
AC
VPC
VCM
OM
EAM
Ken Griffin's VYGR Position: Q1 2026 in Review
Ken Griffin reduced its Voyager Therapeutics (VYGR) stake by 34% in Q1 2026, selling an estimated $756K and leaving 364,664 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #6863.
Ken Griffin first reported a position in VYGR in Q3 2017 and has held it in 32 quarters since. The position peaked at $8.95M in Q3 2020. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.
- Ken Griffin held 364,664 shares of Voyager Therapeutics worth $1.41M as of Q1 2026.
- Ken Griffin sold 191,982 Voyager Therapeutics shares in Q1 2026, an estimated $756K.
- Voyager Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #6863 holding.
- Ken Griffin first reported a position in Voyager Therapeutics in Q3 2017 and has held it in 32 quarters since.
- Ken Griffin's Voyager Therapeutics position peaked at $8.95M in Q3 2020.
- 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.